Osteoarthritis Pain – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Osteoarthritis Pain – Pipeline Review, H2 2016’, provides an overview of the Osteoarthritis Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain

The report reviews pipeline therapeutics for Osteoarthritis Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Osteoarthritis Pain therapeutics and enlists all their major and minor projects

The report assesses Osteoarthritis Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Osteoarthritis Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Addex Therapeutics Ltd

Afferent Pharmaceuticals, Inc.

Akron Molecules AG

Allergan Plc

Ampio Pharmaceuticals, Inc.

Antibe Therapeutics, Inc.

Aralez Pharmaceuticals Inc.

Arena Pharmaceuticals, Inc.

Array BioPharma Inc.

AskAt Inc.

Astellas Pharma Inc.

Axsome Therapeutics Inc

Biogen Inc

Boehringer Ingelheim GmbH

Cara Therapeutics, Inc.

Centrexion Therapeutics Corp

Chromocell Corporation

Eli Lilly and Company

Elite Pharmaceuticals, Inc.

Eupraxia Pharmaceuticals Inc.

Flexion Therapeutics, Inc.

Genzyme Corporation

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd.

Grunenthal GmbH

Iroko Pharmaceuticals, LLC

Medestea Research & Production S.p.A.

MedImmune, LLC

Nuvo Pharmaceuticals Inc.

Pfizer Inc.

Phosphagenics Limited

pSivida Corp.

Purdue Pharma LP

Regeneron Pharmaceuticals Inc

Symic Biomedical, Inc.

Taiwan Liposome Company, Ltd.

Vertex Pharmaceuticals Incorporated

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Osteoarthritis Pain Overview 7

Therapeutics Development 8

Osteoarthritis Pain - Therapeutics under Development by Companies 10

Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes 13

Osteoarthritis Pain - Pipeline Products Glance 14

Osteoarthritis Pain - Products under Development by Companies 18

Osteoarthritis Pain - Products under Investigation by Universities/Institutes 22

Osteoarthritis Pain - Companies Involved in Therapeutics Development 23

Osteoarthritis Pain - Therapeutics Assessment 62

Drug Profiles 77

Osteoarthritis Pain - Dormant Projects 187

Osteoarthritis Pain - Discontinued Products 192

Osteoarthritis Pain - Product Development Milestones 194

Appendix 204

List of Tables

List of Tables

Number of Products under Development for Osteoarthritis Pain, H2 2016 15

Number of Products under Development for Osteoarthritis Pain – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Comparative Analysis by Unknown Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Development by Companies, H2 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Osteoarthritis Pain – Pipeline by AbbVie Inc, H2 2016 30

Osteoarthritis Pain – Pipeline by Addex Therapeutics Ltd, H2 2016 31

Osteoarthritis Pain – Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 32

Osteoarthritis Pain – Pipeline by Akron Molecules AG, H2 2016 33

Osteoarthritis Pain – Pipeline by Allergan Plc, H2 2016 34

Osteoarthritis Pain – Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 35

Osteoarthritis Pain – Pipeline by Antibe Therapeutics, Inc., H2 2016 36

Osteoarthritis Pain – Pipeline by Aralez Pharmaceuticals Inc., H2 2016 37

Osteoarthritis Pain – Pipeline by Arena Pharmaceuticals, Inc., H2 2016 38

Osteoarthritis Pain – Pipeline by Array BioPharma Inc., H2 2016 39

Osteoarthritis Pain – Pipeline by AskAt Inc., H2 2016 40

Osteoarthritis Pain – Pipeline by Astellas Pharma Inc., H2 2016 41

Osteoarthritis Pain – Pipeline by Axsome Therapeutics Inc, H2 2016 42

Osteoarthritis Pain – Pipeline by Biogen Inc, H2 2016 43

Osteoarthritis Pain – Pipeline by Boehringer Ingelheim GmbH, H2 2016 44

Osteoarthritis Pain – Pipeline by Cara Therapeutics, Inc., H2 2016 45

Osteoarthritis Pain – Pipeline by Centrexion Therapeutics Corp, H2 2016 46

Osteoarthritis Pain – Pipeline by Chromocell Corporation, H2 2016 47

Osteoarthritis Pain – Pipeline by Eli Lilly and Company, H2 2016 48

Osteoarthritis Pain – Pipeline by Elite Pharmaceuticals, Inc., H2 2016 49

Osteoarthritis Pain – Pipeline by Eupraxia Pharmaceuticals Inc., H2 2016 50

Osteoarthritis Pain – Pipeline by Flexion Therapeutics, Inc., H2 2016 51

Osteoarthritis Pain – Pipeline by Genzyme Corporation, H2 2016 52

Osteoarthritis Pain – Pipeline by GlaxoSmithKline Plc, H2 2016 53

Osteoarthritis Pain – Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 54

Osteoarthritis Pain – Pipeline by Grunenthal GmbH, H2 2016 55

Osteoarthritis Pain – Pipeline by Iroko Pharmaceuticals, LLC, H2 2016 56

Osteoarthritis Pain – Pipeline by Medestea Research & Production S.p.A., H2 2016 57

Osteoarthritis Pain – Pipeline by MedImmune, LLC, H2 2016 58

Osteoarthritis Pain – Pipeline by Nuvo Pharmaceuticals Inc., H2 2016 59

Osteoarthritis Pain – Pipeline by Pfizer Inc., H2 2016 60

Osteoarthritis Pain – Pipeline by Phosphagenics Limited, H2 2016 61

Osteoarthritis Pain – Pipeline by pSivida Corp., H2 2016 62

Osteoarthritis Pain – Pipeline by Purdue Pharma LP, H2 2016 63

Osteoarthritis Pain – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 64

Osteoarthritis Pain – Pipeline by Symic Biomedical, Inc., H2 2016 65

Osteoarthritis Pain – Pipeline by Taiwan Liposome Company, Ltd., H2 2016 66

Osteoarthritis Pain – Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 67

Osteoarthritis Pain – Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 68

Assessment by Monotherapy Products, H2 2016 69

Assessment by Combination Products, H2 2016 70

Number of Products by Stage and Target, H2 2016 72

Number of Products by Stage and Mechanism of Action, H2 2016 76

Number of Products by Stage and Route of Administration, H2 2016 81

Number of Products by Stage and Molecule Type, H2 2016 83

Osteoarthritis Pain – Dormant Projects, H2 2016 194

Osteoarthritis Pain – Dormant Projects (Contd..1), H2 2016 195

Osteoarthritis Pain – Dormant Projects (Contd..2), H2 2016 196

Osteoarthritis Pain – Dormant Projects (Contd..3), H2 2016 197

Osteoarthritis Pain – Dormant Projects (Contd..4), H2 2016 198

Osteoarthritis Pain – Discontinued Products, H2 2016 199

Osteoarthritis Pain – Discontinued Products (Contd..1), H2 2016 200

List of Figures

List of Figures

Number of Products under Development for Osteoarthritis Pain, H2 2016 15

Number of Products under Development for Osteoarthritis Pain – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 69

Assessment by Combination Products, H2 2016 70

Number of Products by Top 10 Targets, H2 2016 71

Number of Products by Stage and Top 10 Targets, H2 2016 71

Number of Products by Top 10 Mechanism of Actions, H2 2016 75

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 75

Number of Products by Routes of Administration, H2 2016 80

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 80

Number of Products by Molecule Types, H2 2016 82

Number of Products by Stage and Molecule Types, H2 2016 82

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports